Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 239 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Busse WW, Bateman ED, Caplan AL, Kelly W, O'Byrne PM, Rabe KF, Chinchilli VM. Combined analysis of asthma safety trials of long-acting ß2-agonists. N Engl J Med 2018;378:2497-505. [Ref.ID 102733]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White M, Lazarus SC, Blake KV, Lang JE, Baker WL. Association of inhaled corticosteroids and long-acting ß-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma. A systematic review and meta-analysis. JAMA 2018;319:10 de abril. [Ref.ID 102671]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma. A systematic review and meta-analysis. JAMA 2018;319:10 de abril. [Ref.ID 102670]
6. Cita con resumen
Anónimo. Mepolizumab. Australian Prescriber 2017;40:35-6. [Ref.ID 101502]
7. Cita con resumen
Johnston SL, Szigeti M, Cross M, Brightling C, Chaudhuri R, Harrison T, Mansur A, Robison L, Sattar Z, Jackson D, Mallia P, Wong E, Corrigan C, Higgins B, Ind P, Singh D, Thomson NC, Ashby D, Chauhan A, AZALEA Trial Team. Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial. JAMA 2016;176:1630-7. [Ref.ID 100957]
8. Cita con resumen
Fitzgerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Buse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-41. [Ref.ID 100929]
9. Cita con resumen
Bleecker ER, Fitzgerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-27. [Ref.ID 100928]
10.Tiene citas relacionadas
Litonjua AA. Acetaminophen and asthma - A small sigh of relief?. N Engl J Med 2016;375:684-5. [Ref.ID 100713]
11.Tiene citas relacionadas Cita con resumen
Sheehan WJ, Mauger DT, Paul IM, Moy JN, Boehmer SJ, Szefler SJ, Fitzpatrick AM, Jackson DJ, Bacharier LB, Cabana MD, Covar R, Holguin F, Lemanske Jr RF, Martinez FD, Pongracic JA, Beigelman A, Baxi SN, Benson M, Blake K, Chmiel JF, Daines CL, Daines MO, Gaffin JM, Gentile DA, Gower WA, Israel E, Kumar HV, Lang JE, Lazarus SC, Lima JJ, Ly N, Marbin J, Morgan WJ, Myers RE, Olin JT, Peters SP, Raissy HH, Robison RG, Ross K, Sorkness CA, Thyne SM, Wechsler ME, Phipatanakul W, for the NIH/NHLBI AsthmaNet. Acetaminophen versus ibuprofen in young children with mild persistent asthma. N Engl J Med 2016;375:619-30. [Ref.ID 100711]
12.Tiene citas relacionadas Cita con resumen
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NMH, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ß2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44. [Ref.ID 100481]
13.Tiene citas relacionadas Cita con resumen
Chung KF. Dupilumab: a potential new treatment for severe asthma. Lancet 2016;388:3-4. [Ref.ID 100479]
14.Tiene citas relacionadas
Donohue JF. Another choice for prevention of COPD exacerbations. N Engl J Med 2016;374:2284-6. [Ref.ID 100406]
15.Tiene citas relacionadas Cita con resumen
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med 2016;374:2222-34. [Ref.ID 100405]
16. Cita con resumen
Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf 2016;39:501-8. [Ref.ID 100371]
17.Tiene citas relacionadas Cita con resumen
Vestbo J, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Martínez F, Yates J, Newby DE, SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;387:1817-26. [Ref.ID 100248]
18.Tiene citas relacionadas Cita con resumen
Brussele G. Vilanterol fluticasone and mortality in comorbid COPD GOLD B. Lancet 2016;387:1791-2. [Ref.ID 100246]
20. Cita con resumen
Anónimo. Tiotropium - what role in asthma?. Drug Ther Bull 2015;53:102-4. [Ref.ID 99518]
Seleccionar todas
 
 1 a 20 de 239 siguiente >>